Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients

Radiation Oncology

Georges Noël⁵  Gilbert Massard⁴  Jean-Pierre Steib¹  Elisabeth Quoix³  Pierre-Emmanuel Falcoz⁴  Catherine Schumacher²  Nicola Santelmo⁴  Delphine N Antoni⁵  Pierre Truntzer² 

[1] Orthopaedic Department, Hôpital Civil, 1, place de l’Hôpital, Strasbourg cedex, 67091, France;Radiotherapy Department, Centre Paul Strauss, 3, rue de la Porte de l’Hôpital, BP 42, Strasbourg cedex, 67065, France;Pneumology department, Nouvel Hôpital Civil, 1, place de l’Hôpital, Strasbourg cedex, 67091, France;Thoracic surgery department, Nouvel Hôpital civil, 1, place de l’Hôpital, Strasbourg cedex, 67091, France;Radiobiology Laboratory EA 3430, Federation of Translational Medicine in Strasbourg (FMTS), Strasbourg University, Strasbourg, France

关键词: Survival;    Surgery;    Sulcus non-small cell cancer;    Radiotherapy;    Chemotherapy;   

Others  :  1228540
DOI  :  10.1186/s13014-014-0259-6

 received in 2014-08-31, accepted in 2014-11-06,  发布年份 2014

【 摘 要 】

Aims

Retrospective, monocentric analysis of localized superior sulcus non-small cell cancer (SS-NSCLC), article management.

Materials and methods

Between 2000 and 2010, 42 patients have been treated for a SS-NSCLC. Median age was 54.7 years (34.5-86.8). Nineteen tumors (45.2%) were stage IIB, 18 were stage IIIA (42.9%) and 5 were stage IIIB (11.9%). Twenty-two patients were treated by pre-operative radiotherapy or chemoradiotherapy, 20 received exclusive radiotherapy or chemoradiotherapy. Preoperative and exclusive median radiotherapy doses were 46 Gy (40–47 Gy) and 51.8 Gy (40–70 Gy), respectively. All patients treated with chemotherapy received at least platinum. Mean follow up was 44.1 months (0–128 months).

Results

Local, loco-regional and metastatic relapses occurred in 11 (26.2%), 2 (4.8%) and 15 patients (35.7%), respectively. Most common metastatic site was cerebral (7 patients, 46.7%). Median disease-free survival (DFS) was 9.7 months (8.9-10.4). One-, 2- and 5- years DFS rates were 44%, 33% and 26.5%, respectively. No prognostic factor was identified.

Median overall survival (OS) was 22.6 months (10.4-34.8). One-, 2- and 5- years OS rates were 61.9%, 44.9% and 30.1%, respectively. Univariate prognostic factors for OS were WHO (p = 0.027) and tumoral response (p = 0.05). In multivariate analysis, independent favorable prognostic factors were WHO 0–1 (p = 0.017; OR = 0.316 [CI95% 0.123-0.81) and complete response to treatment (p = 0.035; OR = 0.312 [IC95% 0.106-0.919]).

Conclusion

This study highlighted that a good performans status and complete response to treatment are independent factors of OS, whatever the delivered treatment. Brain was the most common metastatic relapse site.

【 授权许可】

   
2014 Truntzer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Rusch VW, Parekh KR, Leon L, Venkatraman E, Bains MS, Downey RJ, Boland P, Bilsky M, Ginsberg RJ: Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Cardiovasc Surg 2000, 119:1147-1153.
• [2]Chardack WM, Maccallum JD: Pancoast tumor; five-year survival without recurrence or metastases following radical resection and postoperative irradiation. J Thorac Surg 1956, 31:535-542.
• [3]Shaw RR, Paulson DL, Kee JL: Treatment of Superior Sulcus Tumor by Irradiation Followed by Resection. Ann Surg 1961, 154:29-40.
• [4]Detterbeck FC: Pancoast (superior sulcus) tumors. Ann Thorac Surg 1997, 63:1810-1818.
• [5]Kunitoh H, Kato H, Tsuboi M, Shibata T, Asamura H, Ichinose Y, Katakami N, Nagai K, Mitsudomi T, Matsumura A, Nakagawa K, Tada H, Saijo N: Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol 2008, 26:644-649.
• [6]Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D: Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001, 121:472-483.
• [7]Girard N, Mornex F: Chemoradiation for locally advanced non-small cell lung cancer. Cancer Radiother 2007, 11:67-76.
• [8]Beneyton V, Billaud G, Niederst C, Meyer P, Bourhala K, Schumacher C, Karamanoukian D, Noel G: Comparison of three dosimetric techniques for lung tumor irradiation. Cancer Radiother 2010, 14:50-58.
• [9]Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y, Carette MF, Rosenwald JC, Cosset JM, Housset M, Touboul E: Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000, 48:1015-1024.
• [10]Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, Li J, Liu X, Wang R, Li B, Kong L, Yin Y: A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007, 30:239-244.
• [11]Attar S, Krasna MJ, Sonett JR, Hankins JR, Slawson RG, Suter CM, McLaughlin JS: Superior sulcus (Pancoast) tumor: experience with 105 patients. Ann Thorac Surg 1998, 66:193-198.
• [12]Komaki R, Roth JA, Walsh GL, Putnam JB, Vaporciyan A, Lee JS, Fossella FV, Chasen M, Delclos ME, Cox JD: Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 2000, 48:347-354.
• [13]Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D: Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007, 25:313-318.
• [14]Goldberg M, Gupta D, Sasson AR, Movsas B, Langer CJ, Hanlon AL, Wang H, Scott WJ: The surgical management of superior sulcus tumors: a retrospective review with long-term follow-up. Ann Thorac Surg 2005, 79:1174-1179.
• [15]Kwong KF, Edelman MJ, Suntharalingam M, Cooper LB, Gamliel Z, Burrows W, Hausner P, Doyle LA, Krasna MJ: High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg 2005, 129:1250-1257.
• [16]Kappers I, Belderbos JS, Burgers JA, van Zandwijk N, Groen HJ, Klomp HM: Non-small cell lung carcinoma of the superior sulcus: favourable outcomes of combined modality treatment in carefully selected patients. Lung Cancer 2008, 59:385-390.
• [17]De Bari B, Lestrade L, Souquet PJ, Pacheco Y, Geriniere L, Guibert B, Mornex F: Single French centre retrospective analysis of local control after high dose radiotherapy with or without chemotherapy and local control for Pancoast tumours. Cancer Radiother 2012, 16:107-114.
• [18]Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY: Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2010, 77:357-366.
• [19]Erasmus JJ, Rohren E, Swisher SG: Prognosis and reevaluation of lung cancer by positron emission tomography imaging. Proc Am Thorac Soc 2009, 6:171-179.
• [20]Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H: Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2011, 29:272-278.
• [21]Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H: Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 2011, 29:279-286.